Fortis Healthcare stock trades 19.04 percent below its yearly high

Fortis Healthcare stock stood at INR 894 on the NSE on September 23, 2026, 19.04 percent below its 52-week high of INR 1,104.30. The valuation picture combines strong quarterly growth with a legal overhang tied to a forensic-audit order.

Q1 revenue reached INR 2,545 crore

For the quarter ended June 30, 2026, Fortis Healthcare reported consolidated revenue of INR 2,545 crore, up 17.5 percent from INR 2,167 crore a year earlier, according to Sahi. The comparison matters because the revenue increase was much faster than the 2.3 percent rise in profit after tax.

Profit after tax reached INR 273 crore, compared with INR 267 crore in Q1 FY26. Economic Times reported that the hospital and diagnostics businesses supported the quarterly performance.

Legal proceedings add a second variable

The operating figures are being assessed alongside a forensic-audit process. A Delhi High Court order was reported in September 2026, while the company said the process did not impose liability or penalties, according to Sahi. That creates a clear split in the investment case: current operations show expansion, while legal developments can influence sentiment and valuation.

Fortis Healthcare's investor page describes an integrated healthcare network with 27 facilities, 4,300 operational beds and 400 diagnostics centers, including joint ventures. The company is listed on the BSE and the National Stock Exchange, according to its Fortis Healthcare investor information.

Stock remains below yearly high

At INR 894 on September 23, 2026, the stock was 19.04 percent below the 52-week high and above the 52-week low of INR 766.80. Market capitalization stood at INR 674,932,584,312 on the same date, giving investors a dated market measure against which to weigh the 17.5 percent revenue increase and the continuing legal proceedings.

More news and analyses on Fortis Healthcare stock